- AdAlta (AD1) teams up with Carina Biotech to combine their treatments to create enhanced cancer therapy
- AdAlta will use Carina’s CAR-T platform which modifies a patient’s immune system to recognise and attack cancer cells that resist standard treatments
- The collaboration will work on up to five tumour antigen targets over the next two years
- If successful, this CAR-T cell therapy could potentially treat a far greater range of cancers than the small number of blood cancers that has been achieved so far
- AdAlta is up 13.3 per cent and is trading at 9.4 cents per share
AdAlta (AD1) has teamed up with Adelaide-based biotech firm, Carina Biotech, to develop next-generation i-body enabled CAR-T cells.
CAR-T cell therapy is a fast-emerging form of cancer therapy that modifies a patient’s immune system to recognise and attack cancer cells that have resisted standard treatments such as chemotherapy and radiation.
The partnership will combine Carina’s advanced CAR-T platform technologies with AdAlta’s i-body.
If successful, this CAR-T cell therapy could potentially treat a far greater range of cancers than the small number of blood cancers that has been achieved so far.
The collaboration will work on up to five tumour antigen targets over the next two years. The first two targets have been selected, with research commencing within the next three months.
AdAlta CEO, Tim Oldham, was pleased with the collaboration agreement.
“We believe that by combining our i-bodies with Carina’s world-class CAR-T platform, we can make this important new therapeutic approach accessible to more patients and a greater range of cancers than is possible today,” Dr Oldham said.
“We are well past the starting line, having worked previously on the first two
targets selected for our collaboration, and with Carina on one of these.”
Carina’s CEO, Deborah Rathjen, was also pleased with the partnership.
“This collaboration with AdAlta gives us the capability to generate bi-specific CAR molecules and then next-generation CAR-T cell products with enhanced cancer targeting and efficacy – something we are very excited about,” Dr Rathjen said.
“The collaboration is off to a great start with Carina having already successfully inserted an AdAlta i-body into a CAR-T cell with functional cancer killing
capability.”
On the market, AdAlta was up 13.3 per cent and trading at 9.4 cents per share at 12:27 pm AEST.